Abstract
We identified NK4, the N-terminal and four kringle domains of hepatocyte growth factor (HGF), as a specific inhibitor of HGF. NK4 binds to the Met/HGF receptor, but does not activate the Met receptor, thereby competitively inhibiting the HGF-Met pathway. Independent of its inhibition of HGF-Met, NK4 acts as an angiogenesis inhibitor. The angioinhibitory action of NK4 is mediated by perlecan, a multidomain proteoglycan involved in vascular basement membrane assembly. The extracellular binding of NK4 to perlecan inhibits cell-associated assembly of fibronectin, and the impaired fibronectin assembly suppresses integrin-dependent angiogenic responses, i.e., endothelial cell proliferation, migration and tube formation. NK4 or an NK4-like fragment is generated by proteases expressed in inflammatory cells, suggesting regulation of physiological or pathological processes by NK4 or NK4-like fragments. In a variety of cancer models, NK4 exhibited anti-cancer effects due to its bifunctional characteristics, including inhibition of invasion and metastasis, inhibition of angiogenesis-dependent tumor growth, and promotion of survival. Several lines of strategies and different molecules that inhibit the HGF-Met pathway have been developed, including small molecular inhibiters of Met tyrosine kinase. The biological action of NK4 as an angiogenesis inhibitor has definite advantages over other molecules. In addition to the well-acknowledged role of HGF-Met in cancer invasion and metastasis, recent studies indicate that activation of the HGF-Met pathway makes tumor-initiating cells invasive and resistant to chemical and radiation therapy. Treatment with NK4 could offer a new therapeutic option for the inhibition of cancer metastasis and growth, and better outcomes for cancer patients.
Keywords: Tumor angiogenesis, hepatocyte growth factor, invasion, Met, metastasis, NK4, tumor-initiating cell
Anti-Cancer Agents in Medicinal Chemistry
Title: Anti-Cancer Approach with NK4: Bivalent Action and Mechanisms
Volume: 10 Issue: 1
Author(s): Takahiro Nakamura, Katsuya Sakai, Toshikazu Nakamura and Kunio Matsumoto
Affiliation:
Keywords: Tumor angiogenesis, hepatocyte growth factor, invasion, Met, metastasis, NK4, tumor-initiating cell
Abstract: We identified NK4, the N-terminal and four kringle domains of hepatocyte growth factor (HGF), as a specific inhibitor of HGF. NK4 binds to the Met/HGF receptor, but does not activate the Met receptor, thereby competitively inhibiting the HGF-Met pathway. Independent of its inhibition of HGF-Met, NK4 acts as an angiogenesis inhibitor. The angioinhibitory action of NK4 is mediated by perlecan, a multidomain proteoglycan involved in vascular basement membrane assembly. The extracellular binding of NK4 to perlecan inhibits cell-associated assembly of fibronectin, and the impaired fibronectin assembly suppresses integrin-dependent angiogenic responses, i.e., endothelial cell proliferation, migration and tube formation. NK4 or an NK4-like fragment is generated by proteases expressed in inflammatory cells, suggesting regulation of physiological or pathological processes by NK4 or NK4-like fragments. In a variety of cancer models, NK4 exhibited anti-cancer effects due to its bifunctional characteristics, including inhibition of invasion and metastasis, inhibition of angiogenesis-dependent tumor growth, and promotion of survival. Several lines of strategies and different molecules that inhibit the HGF-Met pathway have been developed, including small molecular inhibiters of Met tyrosine kinase. The biological action of NK4 as an angiogenesis inhibitor has definite advantages over other molecules. In addition to the well-acknowledged role of HGF-Met in cancer invasion and metastasis, recent studies indicate that activation of the HGF-Met pathway makes tumor-initiating cells invasive and resistant to chemical and radiation therapy. Treatment with NK4 could offer a new therapeutic option for the inhibition of cancer metastasis and growth, and better outcomes for cancer patients.
Export Options
About this article
Cite this article as:
Nakamura Takahiro, Sakai Katsuya, Nakamura Toshikazu and Matsumoto Kunio, Anti-Cancer Approach with NK4: Bivalent Action and Mechanisms, Anti-Cancer Agents in Medicinal Chemistry 2010; 10 (1) . https://dx.doi.org/10.2174/1871520611009010036
DOI https://dx.doi.org/10.2174/1871520611009010036 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Labeling Strategies of Peptides with 18F for Positron Emission Tomography
Current Topics in Medicinal Chemistry Interaction of Small Cationic Peptides with Intact Basement Membranes. A Study Using Intrinsic Optical Signals of Chick Retinas
Current Medicinal Chemistry Endothelin Receptors in Gastrointestinal Smooth Muscle
Current Protein & Peptide Science The Applications of Targeting Anti-Cancer Agents in Cancer Therapeutics
Anti-Cancer Agents in Medicinal Chemistry A New Approach to Locate the Gallbladder from Ultrasound Image Using Intensity Stretching and SOM-based Color Quantization
Current Medical Imaging P-Glycoprotein Mediated Multidrug Resistance Reversal by Phytochemicals: A Review of SAR & Future Perspective for Drug Design
Current Topics in Medicinal Chemistry Molecular Targets for Nutritional Preemption of Cancer
Current Cancer Drug Targets Cell-penetrating Peptide-mediated Nanovaccine Delivery
Current Drug Targets Mechanisms of Tubulin Binding Ligands to Target Cancer Cells: Updates on their Therapeutic Potential and Clinical Trials
Current Cancer Drug Targets Targeting Tumor Angiogenesis in Gastrointestinal Malignancies
Current Angiogenesis (Discontinued) Clinical Pharmacogenetics and Potential Application in Personalized Medicine
Current Drug Metabolism A Cross Sectional Study of Tumors Using Bio-Medical Imaging Modalities
Current Medical Imaging NK Cell, Monocyte and Non T Cell Biomarkers as Prognostic Indicators in Cancer Immunotherapy
Current Cancer Therapy Reviews The Role of Capecitabine in the Management of Tumors of the Digestive System
Reviews on Recent Clinical Trials Biological Activities of Yarrow Species (Achillea spp.)
Current Pharmaceutical Design Hepatobiliary Diseases and Insulin Resistance
Current Medicinal Chemistry Proteomics of Human Pulmonary Surfactant Proteins
Current Proteomics Leukocyte P2 Receptors: A Novel Target for Anti-inflammatory and Antitumor Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma on Cirrhosis: State of the Art and Future Perspectives
Recent Patents on Anti-Cancer Drug Discovery Dithiocarbamate-based coordination compounds as potent proteasome inhibitors in human cancer cells
Mini-Reviews in Medicinal Chemistry